Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.
about
Interventions for mycosis fungoidesPrimary cutaneous lymphomas: diagnosis and treatmentCutaneous T-cell lymphoma: 2014 update on diagnosis, risk-stratification, and managementPruritus Reduction with Systemic Anti-lymphoma Treatments in Patients with Cutaneous T Cell Lymphoma: A Narrative ReviewSystemic therapy for cutaneous T-cell lymphoma: who, when, what, and why?T-cell Lymphoma Epidemiology: the Known and Unknown.Mycosis fungoides and Sézary syndrome: Current challenges in assessment, management and prognostic markers.Increased Levels of Plasma Epstein Barr Virus DNA Identify a Poor-Risk Subset of Patients With Advanced Stage Cutaneous T-Cell LymphomaExtracorporeal photopheresis for the treatment of erythrodermic cutaneous T-cell lymphoma: a single center clinical experience with long-term follow-up data and a brief overview of the literature.Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma.The current management of mycosis fungoides and Sézary syndrome and the role of radiotherapy: Principles and indicationsMedical history, lifestyle, family history, and occupational risk factors for mycosis fungoides and Sézary syndrome: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.Allogeneic hematopoietic cell transplantation for mycosis fungoides and Sezary syndromeThe mutational landscape of cutaneous T cell lymphoma and Sézary syndromeCutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents.Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)Mycosis fungoides in Iranian population: an epidemiological and clinicopathological studyPhase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma.The Role of an Integrated Multidisciplinary Clinic in the Management of Patients with Cutaneous Lymphoma.The Use of Transcriptional Profiling to Improve Personalized Diagnosis and Management of Cutaneous T-cell Lymphoma (CTCL).Novel therapeutic agents for cutaneous T-Cell lymphoma.A rare case of nephrotic syndrome revealing mycosis fungoide managed successfully with chemotherapy.Management of advanced cutaneous T-cell lymphoma: role of the dermatologist in the multidisciplinary teamCutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphomaGenomic profiling of Sézary syndrome identifies alterations of key T cell signaling and differentiation genesDevelopment of a plaque infiltrated with large CD30+ T cells over a silicone-containing device in a patient with history of Sézary syndromeCD30+ Cutaneous T Cell Lymphoma: Response to Rotational Total Skin Electron Irradiation.Use of class I histone deacetylase inhibitor romidepsin in combination regimensCutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model.Elucidating the role of interleukin-17F in cutaneous T-cell lymphomaIncreased Twist expression in advanced stage of mycosis fungoides and Sézary syndromeMycosis fungoides with large cell transformation: clinicopathological features and prognostic factors.Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009.TP53 Gene Status Affects Survival in Advanced Mycosis Fungoides.Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas.miR-223 regulates cell growth and targets proto-oncogenes in mycosis fungoides/cutaneous T-cell lymphoma.Malignant inflammation in cutaneous T-cell lymphoma-a hostile takeoverTreatment algorithms for mature T-cell and natural killer-cell neoplasms.Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management.
P2860
Q24200749-DC6D6744-CB65-4EBE-9F61-D49175DDC69BQ26772207-CBB998C6-2DB1-400A-872F-3AB8A6D1D6EDQ27024076-E096CC5C-D7F3-43E5-86C4-62C0102FA0C8Q28075343-FA3D1818-49CF-48FA-AFF5-925F10F702DFQ30239965-F1D0B62C-4D46-4C07-91F4-775B6D4404C6Q30239985-A933B006-7322-434B-842D-5C876D29401DQ30252152-0B795991-866F-4008-AB07-102FF78F78BFQ30276132-2F49BBD8-AE40-4358-BFB7-4CF7609FFF00Q30650570-B4CE0BAA-46A0-4CEA-B00E-F7EDCD834219Q33417976-9CCA2E06-205C-4D8E-B372-A95B78945CF2Q33746059-A4AB6E82-2EDE-46E5-9358-A22FD1DA7215Q34137936-9634973B-70B4-48B4-802F-522606DC8973Q34459010-02DCBB13-DA6F-4098-87CE-E30E723E8F52Q34501143-1D3C30C2-CE8C-48C2-A698-DC5435705157Q34516083-0A261AC4-651C-4C63-B1A9-F44685B9CC2CQ35022833-392A695D-28FA-42E0-BEA3-8B8BA471A9E9Q35074418-3A18E18E-BA6F-420D-81F6-176EBAD07902Q35222112-4A45E2DA-4A75-4526-B758-FFBE9DA1E4B2Q35750752-27B21149-EFBF-4DF4-B728-8B7380746DA0Q35752062-BA51CA32-1EEF-48E4-B1A2-0E924F402EEFQ36161365-AE0DC76A-D39C-44E3-B92F-B84BC86206D8Q36257948-409088F7-8F98-4FA0-9D4C-625018B03730Q36383242-077807EC-FC6B-4DDF-8C6F-90222CC6FCF1Q36470196-F5259702-01BC-4EA4-9250-660B2C252A90Q36519044-08ECE217-1317-475E-A805-00E802EB6972Q36793430-941761DB-3767-4936-B135-77844DA2FC2AQ36865775-0F92DB0B-E77A-426D-B3C6-2E09C72566E4Q36999986-5587D895-FADA-4888-B66E-A3364EF40314Q37107439-1F86E25F-CFF6-46CF-91C7-5E42EAD3B915Q37163606-DD491803-74A3-4D37-B067-48F54012E2E3Q37216178-A0366257-BBA7-4AC3-A994-1ADFEF4E6965Q37230256-059BAB4F-A5D2-4118-BCA9-78514F3F74E0Q37296614-525100F4-13D0-479D-B7FE-14C5AFD15EB1Q37379370-97F0BE2B-D30A-41CB-9B6C-049C32890E6AQ37407941-B4AA17F3-9961-4FD0-85C1-6A0FB83255D7Q37618920-DF9B85DB-373E-4F2D-A23F-8625FD1E4CA4Q37653005-FCCB0769-180C-4FC7-8184-CFEB42D9227DQ37723390-27ECFC7D-31B9-4057-B72B-9DD06D04A4ECQ37932546-5ECBC275-5B17-4A97-8B05-3D32076E2BC4Q37944565-8B1B2048-C0D7-4F6F-9A87-35F8E4C8CE48
P2860
Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Survival outcomes and prognost ...... nt of Cancer staging proposal.
@en
Survival outcomes and prognost ...... nt of Cancer staging proposal.
@nl
type
label
Survival outcomes and prognost ...... nt of Cancer staging proposal.
@en
Survival outcomes and prognost ...... nt of Cancer staging proposal.
@nl
prefLabel
Survival outcomes and prognost ...... nt of Cancer staging proposal.
@en
Survival outcomes and prognost ...... nt of Cancer staging proposal.
@nl
P2093
P356
P1476
Survival outcomes and prognost ...... ent of Cancer staging proposal
@en
P2093
Alistair Robson
Bridget Wilkins
Catherine M Stefanato
Eduardo Calonje
Elizabeth Mary Wain
Emma Wedgeworth
Julia Scarisbrick
Katherine Webb
Michael Cox
P304
P356
10.1200/JCO.2009.27.7665
P407
P50
P577
2010-09-20T00:00:00Z